Publication date: Jun 04, 2019
This post was originally published on this site IONIS-HTTRx, a potential therapy for Huntington’s disease, was able to reduce the levels of mutant huntingtin (mHTT) protein in early-stage patients, according to results from a Phase 1/2 clinical trial. IONIS-HTTRx, developed by Ionis Pharmaceuticals, is designed to target and destroy all forms of mutated huntingtin protein, which means it has the potential to treat all Huntington’s patients, regardless of their individual HTT mutation. Compared with the start of the study, the median decrease in mutant HTT protein levels among patients given IONIS-HTTRX was 20% in the 10 mg dose group; 25% in the 30 mg group; 28% in the 60 mg group; 42% in the 90 mg group; and 38% in the 120 mg group. The post Investigational IONIS-HTTRx Lowers Mutant Huntingtin Protein in Early-stage Patients, Phase 1/2 Data Show appeared first on Huntington’s Disease News. The post Investigational IONIS-HTTRx Lowers Mutant Huntingtin Protein in Early-stage Patients, Phase 1/2 Data Show appeared first on BioNewsFeeds.
- Targeting Huntingtin Expression in Patients with Huntington’s Disease.
- Fresh Updates from First Huntingtin Lowering Study Publication
- Experimental Drug For Huntington’s Disease Jams Malfunctioning Gene
- Huntington’s disease: New drug successfully lowers levels of the abnormal protein